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Th   e true role of progesterone signaling in breast cancer 
development and progression is not only a subject of 
considerable interest but is also full of controversies. Th  e 
article by Zuo and colleagues [1] in this issue of Breast 
Cancer Research unveils a novel point of view that will 
further rock the ﬁ  eld.
Classically, the perception has been that the physio-
logical actions of progesterone are mediated via nuclear 
progesterone receptors (PRs) that act as transcription 
factors to alter gene expression [2]. However, it has long 
been recognized that some physiological actions of 
pro  gesterone occur far too rapidly and cannot be 
accounted for by its genomic actions [2,3]. In the past 
20  years great strides have been made in identifying 
various progesterone-induced rapid transcription-
indepen  dent (non-genomic) signaling pathways. While 
the existence of progesterone-triggered non-genomic 
signaling is now relatively well accepted [2,3], the 
receptors mediating these actions, as well as the 
physiologic relevance of these extra-nuclear signals, 
continue to be a matter of intense debate [4,5].
Substantial evidence implicates membrane- or 
cytoplasmic-localized classical steroid receptors as 
regulators of non-genomic steroid signaling, and proges-
terone is no exception [3]. It has been shown that in breast 
cancer cells the classical PRB directly interacts with Src to 
mediate progesterone-triggered Src and down  stream 
mitogen-activated protein kinase (MAPK) activation [6]. 
In fact, non-genomic PR signaling appears to promote 
proliferation of breast cancer cell lines under some 
conditions [3], although the clinical relevance of this extra-
nuclear steroid signaling in breast cancer is unclear.
In addition to classical PRs, PGMRC1 (progesterone 
membrane receptor component-1) [3,7,8] has been 
implicated in membrane-initiated progesterone signaling. 
PGMRC1 was ﬁ   rst thought to be a regulator of the 
progesterone-induced acrosomal reaction in sperm. 
More recently PGMRC1 has been reported to mediate 
anti-apototic functions of progesterone in granulosa/
luteal cells [3,7,8]. However, despite these intriguing 
observations, stringent progesterone binding studies 
have not been performed, and the biological importance 
of PGRMC1 remains controversial. In fact, in liver 
microsomes, PGRMC1 has been shown to serve a 
completely diﬀ  erent function as a potential cofactor for 
cytochrome p450 enzymes [3]. Th   us, further studies are 
needed to establish the speciﬁ  city of PGRMC1 as a PR.
Finally, in recent years, a new family of membrane PRs 
(the mPRs) has emerged as potential receptors for non-
genomic actions of progesterone [3,7]. A vast array of 
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can modulate MAPK signaling, cAMP levels, and 
calcium signaling in response to progesterone [2,3,7,9]. 
Interestingly, despite having essentially no sequence 
homology to G protein-coupled receptors, some com-
puter modeling programs predict mPRs to contain seven 
transmembrane domains [10]. Moreover, studies suggest 
that these receptors regulate cAMP levels via G-protein 
coupled signaling at the plasma membrane [3,9]. 
However, this characterization of mPRs is seriously 
debated by studies questioning the ability of mPRs to 
localize to the plasma membrane, bind to progesterone, 
or regulate G-protein signaling [4,5]. In addition, a recent 
study in yeast showed progesterone-induced signaling to 
be G-protein independent [11]. Th   us, the functional and 
biological roles of the mPR family remain murky.
Despite the fair share of controversies, given the impor-
tance of progesterone actions within and outside the 
reproductive system, especially in the breast, mPRs 
remain an attractive target for therapeutic intervention 
and therefore a subject of intense research. Th   e article by 
Zuo and colleagues [1] provides new and provocative 
insight into the role of mPRs in epithelial to mesenchymal 
transition (EMT), a diﬀ  erentiation process characteristic 
of basal phenotype breast cancer. Th  e authors propose 
that progesterone acts as a negative regulator of EMT in 
a breast cancer cell line through mPRα-mediated mecha-
nisms whereby mPRα interacts with the epidermal 
growth factor receptor and caveolin-1 in the caveolar 
membrane, leading to subsequent inactivation of the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway and 
inhibition of EMT-relevant events as well as proliferation.   
Th   e authors further provide evidence of mPRα expression 
in benign and malignant human breast tissue, with 
especially high levels in triple-negative (no detectable 
estrogen receptor, PR, or Her2/neu) breast cancers. 
Th  ese observations bring forth the possibility that pro-
ges  tin therapy may be beneﬁ  cial in triple-negative breast 
cancers, where their anti-EMT and anti-proliferative 
eﬀ  ects may be most potent.
To date, there is limited physiological evidence of mPR 
actions. mPRs have been implicated to have a role in the 
uterus [3,7,9] and in the negative feedback actions of pro-
ges  terone on the release of gonadotropin-releasing 
hormone [12]. Th   is study by Zuo and colleagues provides 
the stepping stone for establishing another biological 
importance of mPRs in humans. However, like many 
scientiﬁ   c discoveries, the results create perhaps more 
questions than answers. First, the model proposed in this 
study indicates that the anti-EMT eﬀ  ects of progesterone 
are mediated via mPRα by inhibition of PI3K, yet 
progestins are known to activate the PI3K/Akt in many 
other instances [13,14]. In fact, in the supplemental data 
the authors show that progesterone activates Akt 
phosphorylation in their cells. Second, the authors 
describe a negative eﬀ  ect of progesterone via mPRα on 
MB468 cell proliferation, while others have reported a 
proliferative eﬀ  ect of PGRMC1 in the same cell type [15]. 
Th   us, the question arises whether progesterone has both 
proliferative and anti-proliferative eﬀ  ects in breast cancer 
cells, depending upon the cell line and experimental 
setup. Th   ird, the cells used in this study have low, but still 
detectable, levels of classical PR, the expression of which 
rises upon progesterone treatment. In addition, 
expression of PGRMC1 was not investigated. Th  erefore, 
it is still unclear whether mPRα functions as a stand-
alone PR, or whether it works together with other 
receptors to regulate proliferation and EMT. Finally, the 
true biological importance of mPR signaling in breast 
cancer development, or for that matter, in any process, 
cannot be properly assessed until the development of 
better in vivo model systems, including the creation of 
mPR knockout mouse models. Until then the murky 
waters of progesterone signaling in the membrane will 
remain treacherous.
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